Osteoporosis and androgen-depleting drugs in sex offenders [9]

Lancet

Volumn 357, Issue 9263, 2001, Pages 1208-1209

  Gooren, L J G ^a   Lips, P ^a   Gijs, L ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANDROGEN; ANDROGEN RECEPTOR; ANTIANDROGEN; BISPHOSPHONIC ACID DERIVATIVE; CYPROTERONE ACETATE; HORMONE RELEASE INHIBITING FACTOR; LUTEINIZING HORMONE; MEDROXYPROGESTERONE ACETATE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ANDROGEN BLOOD LEVEL; BONE DENSITY; BONE MASS; COGNITIVE THERAPY; HORMONAL THERAPY; HORMONE ACTION; HUMAN; HYPOGONADISM; LETTER; NETHERLANDS; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; SEXUAL CRIME; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0035857946     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)04358-0     Document Type: Letter

References (5)

1. Hormonal and psychopharmacological interventions in the treatment of paraphilias; an update
2. Castrated men exhibit bone loss: Effect of calcitonin treatment on biochemical indices of bone remodeling
3. Osteopororis after orchiectomy for prostate cancer
4. Alendronate for the treatment of osteoporosis in men
5. A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women